– El objetivo es promover la profesionalización y actualización del...Leer más
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1–3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination† with Pfizer-BioNTech or Moderna vaccines against COVID-19–associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19–associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%–99%) for full vaccination and 64% (95% CI = 28%–82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5).
This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19–associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.
Randomized clinical trials of vaccines that have received an EUA in the United States showed efficacy of 94%–95% in preventing COVID-19–associated illness (4,5).§ However, hospitalization is a rare outcome among patients with COVID-19–associated illness of any severity, so most cases detected in the trials did not lead to hospitalization; therefore, the studies had limited power to assess protection against severe COVID-19 among older adults.
Postmarketing observational studies are important to assess VE against COVID-19–associated hospitalizations in adults aged ≥65 years under real-world conditions and to strengthen evidence from clinical trials of vaccine efficacy. A standard approach to postmarketing VE evaluation involves the test-negative design in which vaccine performance is assessed by comparing the odds of antecedent vaccination among case-patients with acute laboratory-confirmed COVID-19 and control-patients without acute COVID-19 (6).
During January 1, 2021–March 26, 2021, adults with COVID-19–like illness¶ admitted to 24 hospitals in 14 states within two networks (the Hospitalized Adult Influenza Vaccine Effectiveness Network [HAIVEN] and the Influenza and Other Viruses in the Acutely Ill [IVY] Network) were enrolled. Patients were eligible if they were aged ≥65 years on the date of hospital admission, received clinical testing for SARS-CoV-2 (the virus that causes COVID-19) by reverse transcription–polymerase chain reaction (RT-PCR) or antigen test within 10 days of illness onset, and had onset of symptoms 0–14 days before admission.
Case-patients were those who received one or more positive test results for SARS-CoV-2. Patients meeting eligibility criteria who received negative SARS-CoV-2 RT-PCR test results served as controls. Baseline demographic and health information, details about the current illness, and SARS-CoV-2 testing history were obtained by patient or proxy interviews with trained study personnel and electronic medical record review. Patients or proxies were asked about SARS-CoV-2 vaccination history including number of doses, dates and location of vaccination, and availability of vaccination record cards documenting receipt. Secondary electronic medical records and state immunization registry searches for SARS-CoV-2 vaccination records were conducted during March 26, 2021–April 19, 2021, for all included patients without vaccination record cards to verify reported or unknown vaccination status.
Participants were considered to have received COVID-19 vaccine doses based on documentation by CDC vaccination record card, state immunization registry search, electronic medical record search, or by plausible self-report if they provided vaccination dates and location. Documented record of vaccination dates was used when any potential discordance was identified between self-reported and documented dates. Participants with unverified COVID-19 testing status or vaccination status, or vaccination with Janssen COVID-19 vaccine (Johnson & Johnson), which was in limited use during the evaluation period, were not included. SARS-CoV-2 vaccination status included four categories: 1) unvaccinated, defined as no receipt of any SARS CoV-2 vaccine before illness onset; 2) single-dose vaccinated <14 days before illness, defined as receipt of the first vaccine dose <14 days before COVID-19–like illness onset; 3) partially vaccinated, defined as receipt of 1 dose of a 2-dose vaccination series (Pfizer-BioNTech or Moderna vaccines) ≥14 days before illness onset or 2 doses, with the second dose received <14 days before illness onset** (7); and 4) fully vaccinated, defined as receipt of both doses of a 2-dose vaccine series, with the second dose received ≥14 days before illness onset. Estimates of VE were calculated by comparing the odds of SARS-CoV-2 vaccination in case-patients and controls using the equation VE = 100% × (1 − odds ratio), determined from logistic regression models (8).
The 95% CIs were calculated as 1 − CIOR, where CIOR is the confidence interval of the odds ratio estimates. Models were adjusted a priori for suspected confounders, including U.S. Census region, calendar month, age (as a continuous variable), sex, and race/ethnicity. Other factors were included in the model if they changed the adjusted odds ratio of vaccination by >5%. Primary VE estimates were stratified by partial versus full vaccination.
VE for patients reporting illness onset <14 days after receipt of the first dose of a 2-dose vaccine was also assessed. Because protective immunity is unlikely to be achieved immediately after vaccination (4,5,7), absence of VE within 14 days of the first dose was used as a proxy indicator of absence of bias in the primary VE estimates (6). Statistical analyses were conducted using SAS (version 9.4; SAS Institute). This activity was reviewed by CDC and the other participating institutions and was conducted consistent with applicable federal law and CDC policy.
Monitoring the effectiveness of SARS-CoV-2 vaccination under routine public health use and specifically against severe outcomes in patients at higher risk, including older adults, is a high priority. In this multistate analysis of adults aged ≥65 years, receipt of an authorized COVID-19 vaccine was associated with significant protection against COVID-19 hospitalization. Effectiveness was 94% among adults who were fully vaccinated and 64% among adults who were partially vaccinated (i.e., onset of COVID-like illness ≥14 days after the first vaccine dose in a 2-dose series but <14 days after the second dose). These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5).
Early reports from Israel have also documented the real-world effectiveness of SARS-CoV-2 vaccination, including among older adults (7,9). However, those postmarketing reports only represented the Pfizer-BioNTech vaccine. In the current report, Pfizer-BioNTech and Moderna vaccine products were equally represented, and approximately one half of the patients were aged ≥75 years, providing evidence of real-world effectiveness of both vaccines against an important measure of severe COVID-19 in older adults. Moreover, in assessing the impact of receiving only a single dose, no significant vaccine effectiveness <14 days after the first dose of a SARS-CoV-2 vaccine was detected.
This suggests that bias is unlikely in the primary estimates of vaccine effectiveness from partial and full vaccination. This also highlights the continued risk for severe illness shortly after vaccination, before a protective immune response has been achieved and reinforces the need for vaccinated adults to continue physical distancing and prevention behaviors, such as use of face masks and recommended hand hygiene at least 14 days after the second dose of a 2-dose vaccine. The findings suggest that SARS-CoV-2 vaccines can reduce the risk for COVID-19–associated hospitalization and, as a consequence of preventing severe COVID-19, vaccination might have an impact on post-COVID conditions (e.g., “long COVID”) and deaths (2,10).
The findings in this report are subject to at least six limitations. First, the CIs for VE estimates were wide because of the small sample size, and the number of participants was too small to assess VE by vaccine product, age group, or underlying conditions. Second, as an interim analysis that included self-reported data, vaccination status might have been misclassified, or participants might have had imperfect recollection of vaccination or illness onset dates. Third, selection bias and residual confounding cannot be excluded. Fourth, although the analysis included hospitalized adults from 14 states, the participants were not geographically representative of the U.S. population. Fifth, the case-control design infers protection based on associations between disease outcome and previous vaccination but cannot establish causation. Finally, duration of VE and VE for nonhospitalized COVID-19 was not assessed.
During January–March 2021, in a multistate network of U.S. hospitals, vaccination was associated with a reduced risk for COVID-19–associated hospitalization among adults aged ≥65 years. These data suggest that continuing to rapidly vaccinate U.S. adults against COVID-19 will likely have a marked impact on COVID-19 hospitalization and might lead to commensurate reductions in post-COVID conditions and deaths (2,10).
Créditos: Comité científico Covid